Strides Pharma Science Ltd has announced that its Singapore-based subsidiary, Strides Pharma Global Pte, has entered into a strategic product development partnership with Kenox Pharmaceuticals Inc. The collaboration is aimed at strengthening Strides’ pipeline of nasal spray products across multiple therapeutic areas for the US market.
Focus on Nasal Spray Therapies
The partnership will focus on the development and regulatory filings of several nasal spray formulations in the United States. While specific product details remain undisclosed, the companies said the collaboration underscores a shared commitment to delivering affordable, high-quality medicines to patients in critical therapeutic categories.
Kenox, a contract development and manufacturing company, specializes in Orally Inhaled and Nasal Drug Products (OINDPs), bringing deep technical expertise in the field. Strides, meanwhile, has been expanding its footprint in complex dosage forms, with nasal sprays identified as a key focus area for growth.
Management Commentary
Aditya Kumar, Executive Director – Business Development at Strides Pharma, said:
“We are excited to announce this partnership with Kenox, which brings significant technical expertise in the OINDP space. Nasal sprays have consistently been a priority for Strides, and this collaboration further strengthens the progress we’ve made in this domain. With ongoing investments in our US facility, these products are a natural extension of our strategy to expand our nasal spray technology portfolio.”
Sitaram Velaga, Founder, President & CEO of Kenox Pharmaceuticals Inc., added:
“This collaboration validates our strengths in the OINDP segment and allows us to leverage our expertise to bring vital drug products to global patients at affordable prices. Together with Strides, we aim to accelerate the development of therapies that enhance access and affordability.”
Strategic Significance
- Market Expansion: The collaboration bolsters Strides’ pipeline in the nasal spray therapeutic space, a growing segment within the US market.
- Technology Integration: Strides’ commercial strengths and US manufacturing capabilities, combined with Kenox’s technical know-how in OINDPs, create a strong synergy.
- Affordability & Access: Both firms emphasised a focus on making cost-effective therapies widely available.
Outlook
The partnership reflects Strides’ broader strategy of diversifying into complex generics and niche therapies, reinforcing its position in regulated markets like the US. For Kenox, the deal provides an opportunity to expand its development capabilities into commercially significant product categories with a partner that has established market presence.
Disclaimer:
This article is intended solely for educational and informational purposes. The securities or companies mentioned are provided as examples and should not be considered as recommendations. Nothing contained herein constitutes personal financial advice or investment recommendations. Readers are advised to conduct their own research and consult a qualified financial advisor before making any investment decisions.
Investments in securities markets are subject to market risks. Please read all related documents carefully before investing.